Is Lorazepam Safe in Pregnancy? Risks Explained

Lorazepam is not considered safe during pregnancy, though the degree of risk depends on when in pregnancy it is used, how much is taken, and how long exposure lasts. It crosses the placenta, reaches the fetus, and has been linked in research to higher chances of miscarriage, preterm birth, and short-term problems in newborns. What makes lorazepam particularly tricky to evaluate is that the conditions it treats, primarily anxiety and panic disorders, themselves carry pregnancy risks, making it hard to separate the drug’s effects from the illness it manages.

Lorazepam Crosses the Placenta Readily

One of the fundamental reasons lorazepam raises concerns is that it does not stay in the mother’s bloodstream. Studies measuring lorazepam levels in umbilical cord blood and amniotic fluid have confirmed that both the active drug and its metabolite cross the placenta. After a standard dose given during labor, lorazepam appears in the fetal circulation, and the unbound (active) fraction is actually higher in the fetal blood than in the mother’s, roughly 21% versus 14%.¹ That difference matters because the unbound drug is what produces effects on the brain and body. The fetus, in other words, gets a proportionally larger pharmacological hit than the mother does.

Pregnancy itself also changes how a woman’s body handles lorazepam. The drug is cleared faster during pregnancy because the liver’s capacity to process it through a specific metabolic pathway increases. While faster clearance might seem protective, it can also mean women need higher doses to manage their symptoms, which in turn increases fetal exposure.² This creates a cycle that clinicians find genuinely difficult to manage.

Does Lorazepam Cause Birth Defects?

Decades ago, early reports suggested that benzodiazepines taken in the first trimester might increase the risk of oral clefts (cleft lip or cleft palate). This alarm drove much of the lasting concern about the entire drug class. However, more recent and larger studies have not confirmed that link. A population-based cohort study of first-trimester benzodiazepine exposure in South Korea found no increased risk of oral cleft.³ A critical overview pooling twelve studies reached a similar conclusion: first-trimester benzodiazepine exposure does not appear to be associated with an increased risk of major congenital malformations overall.⁴

This is reasonably reassuring news for women who took lorazepam before realizing they were pregnant. It does not mean the drug is harmless in the first trimester, since the other risks discussed below still apply, but the specific fear of structural birth defects appears to have been overblown by earlier, smaller studies that could not adequately control for other factors.

Miscarriage Risk

A more concerning signal has emerged around miscarriage. A study tracking newly prescribed benzodiazepines in early pregnancy found that lorazepam specifically was associated with roughly a 75% higher risk of spontaneous abortion. Lorazepam was also the most commonly prescribed benzodiazepine in that cohort, accounting for about 45% of all prescriptions.⁵ A more recent meta-analysis confirmed a statistically significant increased risk of miscarriage for lorazepam, with a pooled odds ratio of about 1.48, meaning roughly a 48% higher chance compared to unexposed pregnancies.⁶

These numbers are not trivial, but they come with a significant caveat explored later in this article: the women taking lorazepam had anxiety or panic disorders, which themselves may contribute to miscarriage risk through stress hormones, disrupted sleep, and other physiological pathways. Separating the drug from the disease is the central challenge in all of this research.

Preterm Birth and Low Birth Weight

The association between benzodiazepine use during pregnancy and earlier delivery has been observed repeatedly across different countries and study designs, though the magnitude of the risk varies widely depending on how researchers account for other medications and underlying conditions.

A U.S. cohort study found that benzodiazepine use during pregnancy was linked to substantially higher odds of preterm delivery. Lorazepam, which was the most frequently used benzodiazepine in that group, was associated with nearly eight times the odds of preterm birth, and benzodiazepine use overall was associated with over seven times the odds of low birth weight.⁷ Those are striking numbers, but the study included many women taking multiple psychotropic medications simultaneously, which inflates the apparent effect.

Research designs that more carefully adjust for confounders find a smaller but still real effect. A Norwegian study that controlled for a broad range of baseline factors found that benzodiazepine or related hypnotic use during pregnancy was linked to births about two days earlier on average, roughly 79 grams lower birth weight, and about a 41% higher risk of preterm delivery.⁸ A Japanese case-control study landed somewhere in the middle, finding about double the odds of preterm birth among benzodiazepine-exposed pregnancies.⁹

The range of estimates across studies, from a modest increase to a dramatic one, is itself informative. It tells you that the true effect of the drug alone is probably more moderate than the most alarming numbers suggest, but that some real elevation in preterm birth risk likely exists.

Neonatal Effects from Late Pregnancy Use

The timing of lorazepam exposure matters enormously, and the strongest evidence of harm involves use in late pregnancy. Babies exposed to benzodiazepines in the late third trimester or during labor can experience what is sometimes called “floppy infant syndrome,” characterized by low muscle tone, excessive sedation, and difficulty feeding. Some infants instead show signs of withdrawal, including irritability, tremors, and disturbed sleep. In more severe cases, breathing difficulties and episodes where the baby turns blue have been reported.¹⁰

Not every exposed baby develops these symptoms. But the risk is high enough that clinicians generally try to avoid benzodiazepine use close to delivery whenever possible. When stopping the medication is not feasible, delivery teams prepare for the possibility of a sedated newborn who may need extra support with breathing and feeding in the first days of life.¹¹

The neonatal effects are typically short-lived, resolving within days to weeks as the baby clears the drug. However, whether there are subtler long-term consequences of this early-life sedation is less clear.

Long-Term Neurodevelopmental Questions

Parents understandably worry about whether prenatal benzodiazepine exposure could affect a child’s brain development over the long term, affecting behavior, attention, or learning. The honest answer is that the research here is frustratingly inconclusive.

A systematic review examining the full range of neurodevelopmental outcomes, including cognitive, emotional, behavioral, and motor development, found that while some studies did report associations between prenatal benzodiazepine exposure and adverse outcomes, the overall body of research was too thin and methodologically inconsistent to draw firm conclusions.¹²

One large study deserves specific mention because it illustrates the problem of confounding. Researchers initially found that benzodiazepine exposure during pregnancy was linked to modestly higher rates of ADHD and autism spectrum disorder in children. But when they compared exposed children to their own unexposed siblings, essentially controlling for shared genetics and family environment, the associations vanished. Exposed siblings were no more likely to develop ADHD or autism than their unexposed brothers and sisters.¹³ This strongly suggests that what looked like a drug effect was actually driven by the family characteristics, whether genetic or environmental, that led to the prescription in the first place.

Why the Evidence Is So Hard to Interpret

A theme running through nearly every study on lorazepam in pregnancy is something researchers call confounding by indication. The women who take lorazepam during pregnancy are not a random sample. They are women with anxiety disorders, panic attacks, insomnia, or other conditions severe enough to warrant medication during a time when most people try to avoid drugs. Those underlying conditions themselves affect pregnancy outcomes. Severe anxiety raises cortisol levels, disrupts sleep, and may affect placental blood flow. Women with psychiatric conditions are more likely to smoke, use other substances, and have co-occurring medical problems.¹⁴

You cannot ethically run a randomized controlled trial where you assign pregnant women to take lorazepam or a placebo. So researchers must rely on observational data and try to statistically adjust for the differences between women who take the drug and women who do not. Even the most sophisticated adjustments cannot fully account for unmeasured factors. The sibling comparison study on ADHD and autism, described above, is one of the more creative attempts to get around this problem, and its findings suggest that much of the apparent risk in other studies may reflect the condition rather than the medication.

This does not mean lorazepam is safe. It means the true size of the risk, stripped of all confounders, is probably smaller than the raw numbers in most studies imply. For clinical decision-making, the uncertainty itself matters. When you cannot be sure whether a drug is causing harm or merely traveling alongside it, caution is the default.

Practical Guidance and How Decisions Get Made

Given the mixed evidence, guidelines generally treat lorazepam as a drug to avoid in pregnancy when possible, reserving it for situations where safer alternatives have failed or are inappropriate. One review explicitly concluded that lorazepam should only be used in severe or life-threatening cases of anxiety-related conditions for which safer drugs are not available or effective.¹⁵

In practice, though, the decision is rarely a simple yes or no. For a woman with occasional mild anxiety, switching to non-pharmacological approaches like cognitive behavioral therapy is usually straightforward. For a woman with severe panic disorder who is already on lorazepam when she becomes pregnant, abruptly stopping the drug can trigger withdrawal symptoms that are themselves dangerous, including seizures in cases of physical dependence. In clinical settings managing pregnant women with benzodiazepine dependence, structured tapering protocols are used, often guided by symptom severity to minimize both withdrawal risk and total drug exposure.¹⁶

The key principle is that the decision should balance the risks of the medication against the risks of the untreated condition. Severe, uncontrolled anxiety during pregnancy is not a benign state. If the options come down to lorazepam or psychiatric crisis, clinicians may judge that carefully monitored, short-term use at the lowest effective dose is the lesser harm. That calculation changes throughout pregnancy, with extra caution near delivery to minimize the chance of neonatal sedation or withdrawal.

What About Breastfeeding?

Many women who took lorazepam during pregnancy, or who develop postpartum anxiety, wonder whether it is safe to breastfeed while on the medication. The answer leans cautiously toward yes for occasional low doses, based on how little drug actually reaches the infant through breast milk.

A pharmacokinetic study measured lorazepam concentrations in breast milk after a standard dose and found that milk levels peaked about 90 minutes after the dose, with a relative infant dose estimated between roughly 1.4% and 1.8% of the mother’s weight-adjusted dose. Even upper-bound estimates stayed below about 4%. No adverse events in breastfed infants have been linked to lorazepam alone when the mother was taking it without other sedating drugs; the reported cases of central nervous system symptoms in infants all involved mothers on multiple medications simultaneously.¹⁷

A relative infant dose below 10% is a commonly used threshold for judging medication compatibility with breastfeeding, so lorazepam falls well within that range. Still, premature infants and newborns in the first few weeks of life metabolize drugs more slowly, so extra caution applies for younger or smaller babies. Timing doses right after a feed, rather than right before, can further reduce infant exposure.

When Someone Discovers They Took Lorazepam Before Knowing They Were Pregnant

This is a common scenario, and it is worth addressing directly because of the anxiety it causes. Many pregnancies are unplanned, and a woman may have taken lorazepam during the first weeks before she knew she was pregnant. The reassuring finding is that first-trimester benzodiazepine exposure does not appear to increase the risk of major structural birth defects.⁴ The miscarriage risk is real but modest, and by the time a woman discovers the pregnancy, whatever early risk existed has already either materialized or not.

Stopping lorazepam abruptly at this point, especially if you have been taking it daily, is not necessarily the right move. Benzodiazepine withdrawal itself can cause severe symptoms. The appropriate step is to talk to a prescriber who can help plan either a gradual taper or a switch to a pregnancy-compatible alternative, depending on the severity of the underlying condition and the dose involved.

How Lorazepam Compares to Other Benzodiazepines in Pregnancy

Lorazepam sits in an awkward middle ground among benzodiazepines. It is one of the shorter-acting members of the class, which in theory means less accumulation in the fetus and briefer neonatal effects. On the other hand, it is the benzodiazepine most frequently prescribed in pregnancy-age populations, which means it accounts for a disproportionate share of the exposure data. The meta-analysis on miscarriage risk found that lorazepam and alprazolam both carried statistically significant associations, with similar odds ratios around 1.48.⁶

No benzodiazepine has strong safety data in pregnancy. The differences between individual drugs in the class are small enough that switching from lorazepam to, say, diazepam or clonazepam is unlikely to meaningfully reduce risk. The bigger decision is whether a benzodiazepine is truly necessary at all, rather than which specific one to use. When the answer is that some form of medication is unavoidable, clinicians tend to prefer whichever drug the patient is already stable on at the lowest effective dose, rather than introducing a new one and the instability that comes with switching.

Non-Drug Alternatives That Have Evidence

For mild to moderate anxiety during pregnancy, non-pharmacological options are generally preferred and can be genuinely effective. Cognitive behavioral therapy remains the most studied and best-supported approach for anxiety disorders during pregnancy. Structured relaxation techniques, mindfulness-based stress reduction, and regular physical activity all have evidence supporting their use in pregnant populations, though the effect sizes are smaller than medication for severe conditions.

When pharmacotherapy is needed, SSRIs (selective serotonin reuptake inhibitors) are generally considered the first-line medication class for anxiety in pregnancy, as they have a larger and more reassuring safety database than benzodiazepines. They take weeks to reach full effect, which is why benzodiazepines are sometimes used as a bridge in urgent situations. The ideal trajectory for someone managing anxiety in pregnancy is to build non-drug coping strategies and, if needed, an SSRI for ongoing management, while using a benzodiazepine only briefly and at the lowest possible dose during acute episodes.